An observational study in Oral and Throat Cancer, Oropharyngeal Squamous Cell Carcinoma and Oral Squamous Cell Carcinoma, sponsored by Viome. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-29.
Sponsored by Viome · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States — 213 open to participants now, 347 under way, 28 of them phase 3. Squamous Cell Carcinoma of Head and Neck · United States.
Among the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, this one is the 6th largest by planned enrollment of the 62 observational ones that give a count, is one of 61 that started in 2025, is one of 62 observational ones, reaches primary completion later than 83 of the 346 other live ones, and was the 936th registered.
2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.
Browse Squamous Cell Carcinoma of Head and Neck studies →213 of the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
University of Miami · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
Mayo Clinic · Sites in United States
Ages 18+
West Virginia University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,099 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 519 · Phase 2 528 · Phase 3 83 · Phase 4 4
First in 1988; this study’s year is marked. 61 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 100 across 237 observational studies indexed under Squamous Cell Carcinoma of Head and Neck.
Median enrollment 41 across the 994 interventional studies, 132 across the 62 observational. Of the 690 that completed or were terminated, 288 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
420 of 1,099 have an industry lead sponsor. The 10 most frequent:
Viome is the lead sponsor of 25 studies on the registry; 13 are open to participants now.
Viome has 2 studies filed under Squamous Cell Carcinoma of Head and Neck — fewer than ten, so there is no comparison to draw.
106 of the studies in Squamous Cell Carcinoma of Head and Neck with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06998069Phase 3Brown UniversityHead and Neck Cancer Study Project in the Geriatric Population | 2026-12-01 |
| NCT06064877Phase 3AVEO Pharmaceuticals, Inc.A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma | 2027-08 |
| NCT04965792Dana-Farber Cancer InstitutePost-treatment Surveillance in HPV+ Oropharyngeal SCC | 2026-11 |
| NCT02955290Roswell Park Cancer InstituteCIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer | 2026-11-25 |
| NCT05996432Vanderbilt-Ingram Cancer CenterImage-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy | 2026-11-30 |
Add all 106 to your calendar (.ics) → With an account.
Among the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A total of at least 1,000 participants with suspicion of cancer including at least 107 subjects who will be diagnosed with OSCC or OPSCC will be enrolled from either primary or secondary care centers in the U.S. Clinicians will use Viome collection kits to collect saliva samples from eligible patients.
This is a prospective, multi-center study. Subjects with OSCC or OPSCC will be enrolled from four primary and secondary care centers in the U.S. Study samples will be collected by the clinicians at the study sites using Viome saliva sample collection kits. Patients will continue with their current health plan and confirm diagnosis following the standard of care of surgical biopsy with histology if needed. If a biopsy is performed, the result of the biopsy will be compared with the result of the Viome kit. If no biopsy is performed, the Viome test result will be compared with the physician's assessment based on clinical judgment. Patients with a positive result from histology will not receive the results of the Viome kit, and it will not play any part in the clinical management of the patients.
The study population will comprise patients who attend (1) a primary care center (typically dentist offices) and are identified with a suspicion of cancer based on a clinical presentation or (2) a secondary care center (typically hospitals) following the finding of a suspicious lesion or symptom. Secondary care centers include clinical sites where specialists such as oncologists or oral and maxillofacial surgeons (also called head and neck surgeons) perform visual and tactile oral examinations and biopsies to detect oral cancer. They are also known as ear, nose, and throat (ENT) doctors or otolaryngologists.
Women or minorities are not excluded from this study. In order to calculate an estimated number of samples in each demographic category we performed stratified random sampling. We used the SEER Program to calculate oral and throat cancer prevalence for each of the demographic categories.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
OSCC case cohort will consist of patients with Oral Squamous Cell Carcinoma (all stages, locations), recruited from either primary or secondary care.
Device: Oral/Throat cancer test
OPSCC case cohort will consist of patients with Oral Squamous Cell Carcinoma (all stages, locations), recruited from either primary or secondary care.
Device: Oral/Throat cancer test
Participants will be recruited following clinical adjudication with self-reported confirmation of no cancer and from primary and secondary care facilities.
Device: Oral/Throat cancer test
The Oral/Throat cancer test is intended for the qualitative detection of molecular features (human genes, microbial species and functions) associated with Oral Squamous Cell Carcinoma (OSCC) or OroPharyngeal Squamous Cell Carcinoma (OPSCC) in saliva samples from adults with a suspicion of cancer. A positive result from CDOT may indicate the presence of OSCC or OPSCC. The device is intended as a diagnostic aid for clinicians when assessing patients with suspected OSCC or OPSCC who may benefit from follow-up diagnosis and treatment. The device is not intended for a definitive diagnosis.
Sensitivity
Oral/Throat cancer test's ability to designate an individual with disease as positive
Time frame: Through study completion, an average of 18 months
Specificity
Oral/Throat cancer test's ability to designate an individual who does not have a disease as negative
Time frame: Through study completion, an average of 18 months
Positive Post Test Probability (PPV)
The probability of having the target condition if the test falls out positive
Time frame: Through study completion, an average of 18 months
Negative Post Test Probability (NPV)
The probability of having the target condition if the test falls out negative
Time frame: Through study completion, an average of 18 months
Sensitivity by care center (primary and secondary)
Oral/Throat cancer test's ability to designate an individual with disease as positive
Time frame: Through study completion, an average of 18 months
Sensitivity by age
Oral/Throat cancer test's ability to designate an individual with disease as positive
Time frame: Through study completion, an average of 18 months
Sensitivity by sex
Oral/Throat cancer test's ability to designate an individual with disease as positive
Time frame: Through study completion, an average of 18 months
Sensitivity by race
Oral/Throat cancer test's ability to designate an individual with disease as positive
Time frame: Through study completion, an average of 18 months
Sensitivity by smoking history
Oral/Throat cancer test's ability to designate an individual with disease as positive
Time frame: Through study completion, an average of 18 months
Sensitivity by oral cancer type (OSCC or OPSCC)
One measure post treatment
Time frame: Through study completion, an average of 18 months
Sensitivity by disease stage (I, II, III, and IV)
Oral/Throat cancer test's ability to designate an individual with disease as positive
Time frame: Through study completion, an average of 18 months
Sensitivity by metastasis
Oral/Throat cancer test's ability to designate an individual with disease as positive
Time frame: Through study completion, an average of 18 months
Sensitivity by HPV status
Oral/Throat cancer test's ability to designate an individual with disease as positive
Time frame: Through study completion, an average of 18 months
Sensitivity by recurrent cancer
Oral/Throat cancer test's ability to designate an individual with disease as positive
Time frame: Through study completion, an average of 18 months
Specificity by care center (primary and secondary)
One measure post treatment
Time frame: Through study completion, an average of 18 months
Specificity by age
Oral/Throat cancer test's ability to designate an individual who does not have a disease as negative
Time frame: Through study completion, an average of 18 months
Specificity by sex
Oral/Throat cancer test's ability to designate an individual who does not have a disease as negative
Time frame: Through study completion, an average of 18 months
Specificity by race
Oral/Throat cancer test's ability to designate an individual who does not have a disease as negative
Time frame: Through study completion, an average of 18 months
Specificity by smoking history
Oral/Throat cancer test's ability to designate an individual who does not have a disease as negative
Time frame: Through study completion, an average of 18 months
Specificity by oral cancer type (OSCC or OPSCC)
Oral/Throat cancer test's ability to designate an individual who does not have a disease as negative
Time frame: Through study completion, an average of 18 months
Specificity by disease stage (I, II, III, and IV)
Oral/Throat cancer test's ability to designate an individual who does not have a disease as negative
Time frame: Through study completion, an average of 18 months
Specificity by metastasis
Oral/Throat cancer test's ability to designate an individual who does not have a disease as negative
Time frame: Through study completion, an average of 18 months
Specificity by HPV status
Oral/Throat cancer test's ability to designate an individual who does not have a disease as negative
Time frame: Through study completion, an average of 18 months
Specificity by recurrent cancer
Oral/Throat cancer test's ability to designate an individual who does not have a disease as negative
Time frame: Through study completion, an average of 18 months
Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.
Of 117 observational studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 77 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 132. This study's planned 23 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Squamous Cell Carcinoma of Head and Neck →